Literature DB >> 29288817

Low Body Mass Index Is Associated with Increased Risk of Acute GVHD after Umbilical Cord Blood Transplantation in Children and Young Adults with Acute Leukemia: A Study on Behalf of Eurocord and the EBMT Pediatric Disease Working Party.

Annalisa Paviglianiti1, Jean Hugues Dalle2, Mouhab Ayas3, Jan Jaap Boelens4, Fernanda Volt5, Anna Paola Iori6, Mair Pedro de Souza7, Miguel Angel Diaz8, Gerard Michel9, Franco Locatelli10, Charlotte Jubert11, Ibrahim Yakoub-Agha12, Henrique Bittencourt13, Yves Bertrand14, Chantal Kenzey5, Karina Tozatto Maio5, Hiromi Hayashi5, Vanderson Rocha15, Peter Bader16, Eliane Gluckman5, Annalisa Ruggeri17.   

Abstract

Body mass index (BMI) may influence outcomes after allogeneic hematopoietic stem cell transplantation (HSCT). However, the impact of BMI on survival in children undergoing HSCT is not well defined, with conflicting results being reported on this issue. We analyzed 855 patients age 2 to 20 years with diagnosis of acute leukemia who underwent umbilical cord blood transplantation (UCBT) from 1990 to 2015. Patients were classified according to BMI as normal (fifth to 85th percentile), underweight (less than fifth percentile), overweight (85th to 95th percentile), and obese (>95th percentile) using growth charts for age and sex. All patients received single-unit UCBT after a myeloablative conditioning regimen. Diagnosis was acute lymphoblastic leukemia in 68% of the patients. Sixty-one percent of patients (n = 523) were in the normal BMI category, 11% (n = 96) were underweight, 16% (n = 137) overweight, and 12% (n = 99) obese. The cumulative incidence of grade II to IV acute graft-versus-host disease (aGVHD) was 35% (32% to 38%). According to pretransplantation BMI, aGVHD was 46% (33% to 59%) for underweight, 34% (31% to 42%) for normal, 36% (18% to 38%) for overweight, and 27% (15% to 37%) for obese (P = .04). In multivariate analysis, a BMI less than the fifth percentile was associated with higher incidence of acute grade II to IV GVHD compared with normal-BMI patients (hazard ratio,  1.61; 95% confidence interval, 1.15 to 2.26; P = .006). Our results show that being underweight at the time of transplantation is associated with an increased risk of aGVHD, highlighting the importance of nutritional status before UCBT.
Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute leukemia; Body mass index; Children; Umbilical cord blood transplantation; Young adults

Mesh:

Year:  2017        PMID: 29288817     DOI: 10.1016/j.bbmt.2017.12.790

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  4 in total

1.  Unrelated cord blood transplantation and post-transplant cyclophosphamide.

Authors:  Andrea Bacigalupo; Simona Sica; Luca Laurenti; Federica Sora'; Sabrina Giammarco; Elisabetta Metafuni; Idanna Innocenti; Francesco Autore; Luciana Teofili; Maria Bianchi; Patrizia Chiusolo
Journal:  Haematologica       Date:  2018-12-20       Impact factor: 9.941

Review 2.  Association of obesity with mortality and clinical outcomes in children and adolescents with transplantation: A systematic review and meta-analysis.

Authors:  Mehdi Yaseri; Elham Alipoor; Atefeh Seifollahi; Mahtab Rouhifard; Shiva Salehi; Mohammad Javad Hosseinzadeh-Attar
Journal:  Rev Endocr Metab Disord       Date:  2021-03-17       Impact factor: 6.514

Review 3.  A Review on the Impact of Body Mass Index on Outcomes in Pediatric Leukemia.

Authors:  Annalisa Paviglianiti
Journal:  J Blood Med       Date:  2020-06-18

Review 4.  Current Prophylaxis and Treatment Approaches for Acute Graft-Versus-Host Disease in Haematopoietic Stem Cell Transplantation for Children With Acute Lymphoblastic Leukaemia.

Authors:  Matthias Wölfl; Muna Qayed; Maria Isabel Benitez Carabante; Tomas Sykora; Halvard Bonig; Anita Lawitschka; Cristina Diaz-de-Heredia
Journal:  Front Pediatr       Date:  2022-01-06       Impact factor: 3.418

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.